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ABSTRACT
Wegener granulomatosis is a multisystemic disease associated with high mortality rate and characterized by necrotizing granulomatous vascu-
litis predominantly in the respiratory tract and kidneys. Presence of kidney failure at the time of diagnosis describes a poor prognostic marker. 
We presented a Wegener granulomatosis case complicated with brain abscess caused by Nocardia. (JAREM 2016; 6: 126-8)
Keywords: Rapidly progressive glomerulonephritis, acute kidney failure, immunosuppression, infection
INTRODUCTION
Wegener’s granulomatosis (WG) is a multisystemic disease that is 
associated with a high mortality rate and is characterized by nec-
rotizing granulomatous vasculitis, predominantly in the respira-
tory tract and kidneys. The presence of kidney failure at the time 
of diagnosis describes a poor diagnostic marker. We present a 
case of WG complicated with brain abscess caused by Nocardia 
during the treatment.
CASE PRESENTATION
A 66-year-old male patient with complaints of fatigue, elevated 
fever, weight loss, hemoptysis, and left ankle pain was examined 
over the course of 2 months in the infectious diseases clinic of a 
hospital. His PPD test revealed that he was anergic, and no infec-
tion or malignancy focus was detected. The patient was admitted 
to the nephrology unit due to disruption observed in his kidney 
function tests. Verbal consent was obtained from the patient.
In his laboratory findings, leucocytes were 10,200/mm3, Hb was 
9.1 g/dL, Hct was 25.3%, thrombocytes were 287,000/mm3, urea 
was 225 mg/dL, creatinine was 12.4 mg/dL, CRP was 52 mg/L, 
and sedimentation rate was 92 mm/h; proteinuria was observed 
in urinalysis, and plenty of erythrocytes were present in his urine 
sediment. Hemodialysis was started. He was positive (+) for anti-
neutrophil cytoplasmic antibodies (c-ANCAs), while complement 
levels were within the normal range. On observing his kidney size 
to be within the normal range in his ultrasonography, kidney biop-
sy was performed with the pre-diagnosis of “rapidly progressive 
glomerulonephritis”. Along with the elevation of sedimentation, 
the presence of c-ANCA positivity, lower respiratory tract involve-
ment, and the compatibility of kidney biopsy findings with Pauci-
immune Type III crescentic glomerulonephritis, the patient was 
diagnosed with WG. He received 500 mg methylprednisolone 
(Prednol; Mustafa Nevzat Pharmaceutical, İstanbul, Turkey) pulse 
treatment for three consecutive days, followed by 750 mg intra-
venous (IV) cyclophosphamide (Endoxan; Eczacıbaşı-Baxter Hos-
pital Products, İstanbul, Turkey) and five sessions of plasmapher-
esis. In the first week of treatment, creatinine levels (creatinine: 
1.2 mg/dL) dropped down. The recommendation of oral prednis-
olone at a dose of monthly 750 mg IV cyclophosphamide+1 mg/
kg was registered in his polyclinic follow-up. In the third month 
of his treatment, the patient was admitted with complaints of 
coughing, elevated fever, and left side pain. Bronchopneumonia 
was detected in his chest computed tomography (CT) (Figure 1). 
IV 2×1000 mg/day ceftriaxone (Desefin; Deva Holding, İstanbul, 
Turkey) and 500 mg/day levofloxacin (Tavanic; Zentiva Medical 
Products, Lüleburgaz, Turkey) were started, and the steroid dose 
was lowered. On the second day of his treatment, the patient 
developed fatigue and loss of balance, and his cranial magnetic 
resonance (MR) imaging showed a brain abscess (Figure 2). Sur-
gical treatment was not recommended because the abscess 
size was larger than 1.5 cm. Samples were obtained via lumbar 
puncture for culture. Antibiotic treatment was expanded to me-
ropenem 3×1000 mg/day (Meronem; AstraZeneca, Macclesfield, 
England) + TMP/SMX (Bactrim; Deva Holding, Istanbul, Turkey). 
Because Nocardia spp. reproduced in his cerebrospinal fluid cul-
ture, the treatment was planned as 8 weeks of parenteral 2×1000 
mg ceftriaxone + 2×160/800 mg trimethoprim/sulfamethoxazole 
(TMP/SMX), followed by 6 months of oral TMP/SMX and monthly 
cranial MR controls. Immunosuppressive treatment directed at 
WG was limited to 16 mg/day methylprednisolone. At present, 
the controls are continued in the fourth month of the treatment, 
and the size of patient’s brain abscess is decreasing and his renal 
functions (serum creatinine level: 1.3 mg/dL) are stable.
DISCUSSION
WG is a necrotizing granulomatosis vasculitis with an unknown 
etiology and a prevalence of 3/100,000; it is observed in the fifth 
decade regardless of sex (1, 2). Its main symptoms are cough-
ing, dyspnea, and hemoptysis. More than 90% of patients have 
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bilateral, multiple nodules and parenchymal infiltrations of vary-
ing sizes, and lung imaging displays abnormalities (3). Pulmonary 
hemorrhage along with kidney function disorder increases the 
mortality rate.
Glomerulonephritis develops in approximately 75% of WG pa-
tients. Histologically, focal necrotizing glomerulonephritis and 
crescentic glomerulonephritis are observed, and they can rapidly 
lead to kidney failure (4). Hematuria, proteinuria, and erythrocyte 
cylinders are observed as urinary findings. Two-thirds of patients 
can have musculoskeletal complaints. Our patient had findings 
related to the kidneys, lungs, and skeletal system.
More than 90% of patients are c-ANCA positive (5, 6). In case of 
lung involvement accompanying hematuria/proteinuria, kidney 
or lung biopsy may need to be performed for a definitive diagno-
sis. Despite the risk of hemorrhage in our uremic patient, kidney 
biopsy was performed in order to plan for the immunosuppres-
sive treatment, given his age. Patients who require dialysis have 
been reported to benefit from an aggressive treatment (7).
Fauci et al. (2) demonstrated in their study that a combination 
therapy of oral steroid + cyclophosphamide leads to 90% remis-
sion. However, because of the adverse effects of medicines, cy-
clophosphamide treatment is recommended to be administered 
parenterally (1, 3). We administered 0.5 g/m2 single-dose IV pulse 
cyclophosphamide once a month for 3 days and 0.5 g/day IV 
methylprednisolone, followed by 1 mg/kg/day oral prednisolone 
follow-up treatment.
In a study comparing the effectiveness of plasmapheresis and 
pulse steroid in patients with kidney failure, the group that un-
derwent plasmapheresis was reported to develop fewer late-
stage kidney failures (8). Deaths are determined to occur within 
3 months after the start of the treatment of this disease, which 
has a high mortality rate. In total, 54% of reported deaths are as-
sociated with infections. While the treatment of our case was on-
going with the diagnosis of lobar pneumonia that developed in 
the third month of immunosuppressive treatment, loss of balance 
occurred, which led to performing cranial MR that showed brain 
abscess in the parietal region. Reproduction of Nocardia spp. in 
the culture taken by lumber puncture established the diagnosis. 
Nocardia is a rare, mortal, and opportunistic gram-positive bac-
terium that is particularly observed in cases with cellular immunity 
disorder (9, 10). Sole central nervous system involvement is very 
rare (9%) (9, 10). Slow growth in culture may result in mortality due 
to delayed diagnosis and treatment.
CONCLUSION
Patients who receive immunosuppressive treatments must be 
closely followed up as high-risk groups with regard to oppor-
tunistic infections, and the treatment of infections must be per-
formed energetically.
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